On the occasion of the visit of the German Chancellor Angela Merkel and the Minister of Economics Harry Glawe at CHEPLAPHARM in Greifswald, CEO Sebastian F. Braun announces further investments of 210 million euros.
This year, CHEPLAPHARM plans to generate a turnover of 237 million euros – twice as much as in the previous year. As a result, the company contributes to strengthening the economic power in the region and securing valuable jobs in Mecklenburg-Western Pomerania.
In the previous year, 340 million euros were predominantly invested into the worldwirde rights for established brands such as the antiobesity drug XENICAL® and the beta blocker DILATREND®. Further 210 million euros are now mobilized, deliberately without applying for any funding. With this investment, the company will not only acquire further international pharmaceutical rights, but also add 50 new, highly-qualyfied jobs to the Hanseatic town of Greifswald. At present, more than 150 employees from 12 different nations are working at CHEPLAPHARM.
In the course of touring through her electoral constituency, Mrs. Angela Merkel (PhD) gained a personal impression of the company’s story of success and its ambitious future plans. After intensive talks with the management board and some employees, the Chancellor was convinced of the company’s achievements and success so far: “It is impressive how CHEPLAPHARM has built up a young and dynamic company here in Mecklenburg-Western Pomerania that is successfully facing international competition in the highly competitive pharma sector and offering its employees a good job and a diverse range of opportunitites for their development.“
Minister Glawe highlighted that CHEPLAPHARM had just recently shown its ability for coping with higher-scale investment, which also generated high growth in the business location Greifswald as well as attractive jobs.
Sebastian F. Braun (CEO) summarized his impressions of the visit as follows: “We are very pleased and honored that the Chancellor and the Minister of Economic Affairs have found the way to us. Even more, we are delighted about their positive appreciation of our efforts to become a Global Player in the pharmaceutical business. It will be an incentive for us to continue growing vigorously and to add, also in the future, one or another highlight to our region by pursuing our ambitious growth strategy.“
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com